• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

August 9, 2022 By Sean Whooley

Tandem Diabetes Care tslim_X2_Insulin_Pump_Front_View_Control-IQ_RGB
Image from Tandem Diabetes

Wells Fargo downgraded Tandem Diabetes Care (Nasdaq:TNDM) as competitors apply pressure to the automated insulin delivery technology developer.

According to SeekingAlpha, analysts led by Larry Biegelsen moved Tandem from “Overweight” to “Underweight” due to bullish expectations on Wall Street as the company’s competition, including Insulet and Medtronic, come to the fore. The street responded in kind, with shares of TNDM down 6.8% at $56 per share in early-morning trading today.

The report said that Biegelsen wrote that there is “downside risk” to estimates on Wall Street from new competition in Tandem’s area’s of growth.

Insulet and its next-generation Omnipod 5 are said to be applying pressure to Tandem’s new patient starts and renewals, while positive feedback on Medtronic’s next-generation MiniMed 780G insulin pump provides another competitive challenge, particularly in terms of growth outside the U.S., analysts say.

BTIG analyst Marie Thibault wrote in a report following June’s American Diabetes Association (ADA) Scientific Sessions that a catalyst for the company is conversion from multiple daily injections, which, as suggested by the latest reports, may be threatened by the rise of the competitors in the space.

The analysts do not currently have a “Buy,” “Neutral,” or “Sell” rating for the company.

“We discussed various growth drivers that are expected to propel the company’s installed base from 350,000 users today to its goal of 1 million users by 2027,” Thibault wrote. “These catalysts include the extensive pipeline, diabetes technology and data converging to accelerate conversion from multiple daily injections (MDI), the ongoing renewal tailwind that should mirror historical growth, competitive wins, and expansion outside the U.S. Improving retention should also help drive toward this goal.”

At the ADA sessions, Tandem presented positive data on its t:slim X2 insulin pump with Control-IQ technology, then followed it up last month with the acquisition of infusion set maker Capillary Biomedical.

However, the company’s second-quarter earnings, released last week, represented misses on Wall Street projections and a reduced sales guidance, only compounding the current view on the company’s outlook expressed by Wells Fargo.

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Wall Street Beat Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS